Tesamorelin vs GHRP-6

Overview

Tesamorelin and GHRP-6 both stimulate growth hormone release but through different receptors and with vastly different regulatory status. Tesamorelin is FDA-approved for HIV lipodystrophy, while GHRP-6 remains an unapproved research peptide known for its strong appetite-stimulating effects.

Key Facts

Aspect	Tesamorelin	GHRP-6
Class	GHRH analog	GHRP (ghrelin mimetic)
Structure	44 amino acids	6 amino acids
Target	GHRH receptor	GHS-R1a (ghrelin receptor)
FDA Status	Approved	Not approved
Brand Name	Egrifta	None

Mechanism Comparison

Aspect	Tesamorelin	GHRP-6
Receptor	GHRH-R	GHS-R1a
GH Release	Strong	Strong
Appetite Effect	Minimal	Very strong
Cortisol Effect	Minimal	Increases
Prolactin Effect	Minimal	Increases

Key Mechanistic Differences

Tesamorelin:

• Mimics natural GHRH
• Selective for GH release
• Maintains physiological pulsatility
• Minimal off-target effects

GHRP-6:

• Mimics ghrelin signaling
• Strong appetite stimulation
• Elevates cortisol and prolactin
• Less selective profile

Evidence Comparison

Aspect	Tesamorelin	GHRP-6
Human RCTs	Multiple (FDA approved)	Limited
Regulatory Review	Full FDA review	None
Long-term Safety	Established	Unknown
Publication Quality	High	Low-moderate

Tesamorelin Clinical Data

Trial	Finding
Phase 3	~18% visceral fat reduction
Extension	Sustained effect at 52 weeks
Safety	Well-characterized profile

GHRP-6 Data

• Limited controlled human studies
• Often used in research for GH response testing
• Commonly studied for appetite/food intake research
• No commercial development pursued

Side Effect Comparison

Tesamorelin

Effect	Frequency	Notes
Injection site reactions	Common	Erythema, swelling
Peripheral edema	Common	GH-related
Arthralgia	Common	GH-related
Hyperglycemia	Monitor	Less than GHRPs

GHRP-6

Effect	Frequency	Notes
Appetite increase	Very common	Pronounced hunger
Cortisol elevation	Common	Hormonal effect
Prolactin elevation	Common	Hormonal effect
Gastric effects	Common	Ghrelin pathway
Water retention	Common	GH-related
Flushing	Common	Post-injection

Selectivity Comparison

Effect	Tesamorelin	GHRP-6
GH Release	+++	+++
Appetite	+	++++
Cortisol	+	++
Prolactin	+	++
Selectivity	High	Low

Tesamorelin is notably more selective with fewer off-target effects.

Administration

Aspect	Tesamorelin	GHRP-6
Route	Subcutaneous	Subcutaneous

Regulatory and Quality

Aspect	Tesamorelin	GHRP-6
FDA Status	Approved	Not approved
Quality Control	FDA regulated	None
Prescription	Required	Not applicable
Insurance	May cover (HIV)	Never covered
WADA Status	Prohibited	Prohibited

Cost Comparison

Factor	Tesamorelin	GHRP-6
Approximate Cost	$1,000+/month	Variable (research)
Quality Assurance	Pharmaceutical	Unknown
Availability	Prescription	Gray market

Clinical Applications

Use	Tesamorelin	GHRP-6
HIV Lipodystrophy	FDA approved	Off-label
GH Testing	Alternative	Research use
Body Composition	Evidence in HIV	Anecdotal
Appetite Stimulation	Not indicated	Prominent effect

Key Differences

Factor	Tesamorelin	GHRP-6
Regulatory status	FDA approved	Research chemical
Mechanism	GHRH-R	GHS-R1a
Selectivity	High	Low
Appetite effect	Minimal	Very strong
Cortisol/prolactin	Minimal	Elevates
Quality assurance	Regulated	None
Evidence quality	High	Low

Summary

• Tesamorelin is FDA-approved with high selectivity and established safety profile
• GHRP-6 is an unregulated research peptide with strong appetite effects and low selectivity
• Tesamorelin acts via GHRH receptor; GHRP-6 via ghrelin receptor
• GHRP-6’s appetite stimulation is a major feature/side effect
• Tesamorelin has pharmaceutical-grade quality; GHRP-6 quality is unknown
• Both are prohibited in sport

---

This comparison is for educational purposes only. Tesamorelin requires prescription for approved indication. GHRP-6 is not approved for human use. Consult a healthcare provider for treatment decisions.